Back to today’s briefing

Story perspectives

Gilead Acquires Interius for $350M to Enhance Cancer Therapy

8/22/2025

48 6

Summary

Story summary

Gilead Sciences is acquiring Interius BioTherapeutics for $350 million to improve cancer cell therapy.
The acquisition seeks to streamline treatment processes compared to traditional CAR-T therapies.
Interius is advancing INT2104, an in vivo therapy in Phase 1 trials for blood cancers.
Gilead expects a 23 to 25 cent impact on earnings per share in 2025.

1 of 1

Story summary

Gilead Sciences is acquiring Interius BioTherapeutics for $350 million to improve cancer cell therapy.
The acquisition seeks to streamline treatment processes compared to traditional CAR-T therapies.
Interius is advancing INT2104, an in vivo therapy in Phase 1 trials for blood cancers.
Gilead expects a 23 to 25 cent impact on earnings per share in 2025.